To assess the in vivo tumor-targeting performance of 1G12-DOTA-Gd, we performed T1-weighted MRI in subcutaneous xenograft mouse models of GPC3-negative SNU449 cells or GPC3-positive HepG2 cells, using DOTA-Gd as the control (Figure 2a). The gene discussed is GPC3; the disease is neoplasm.